New hope for rare sarcoma patients: AL3818 drug trial underway

NCT ID NCT03016819

Recruiting now Disease control Sponsor: Advenchen Laboratories, LLC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests the drug AL3818 (anlotinib) in people with advanced alveolar soft part sarcoma, leiomyosarcoma, or synovial sarcoma. Currently, only patients with alveolar soft part sarcoma are being enrolled. Participants receive AL3818 pills or a standard chemotherapy drug (dacarbazine). The goal is to see if AL3818 can shrink tumors or slow cancer growth better than current options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AL3818 (anlotinib, catequentinib) hydrochloride
What this could lead to: If successful, this could provide a new treatment option for people with advanced alveolar soft part sarcoma, a rare cancer with limited therapies.
What could go wrong: This is a phase 3 trial, but it's still experimental. The drug may not work better than existing treatments, and side effects like fatigue, high blood pressure, or liver issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alveolar soft part sarcoma leiomyosarcoma sarcoma soft tissue sarcoma synovial sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALVEOLAR SOFT PART SARCOMA LEIOMYOSARCOMA SOFT TISSUE SARCOMA SYNOVIAL SARCOMA

Contacts and locations

Locations

Beijing Cancer Hospital
COMPLETED

Beijing, China
Columbia University Medical Center
WITHDRAWN

New York, New York, 10032, United States
Hospital de la Santa Creu i Sant Pau
COMPLETED

Barcelona, Spain
Istituto Nazionale dei Tumori
COMPLETED

Milan, Italy
MD Anderson Cancer Center
COMPLETED

Houston, Texas, 77030, United States
Mayo Clinic Arizona
COMPLETED

Phoenix, Arizona, 85054, United States
Mayo Clinic Jacksonville
COMPLETED

Jacksonville, Florida, 32224, United States
Mayo Clinic Rochester
COMPLETED

Rochester, Minnesota, 55905, United States
Northwestern University
COMPLETED

Chicago, Illinois, 60611, United States
Royal Marsden Hospital
NOT_YET_RECRUITING

London, SW3 6JJ, United Kingdom
Sarcoma Oncology Center
RECRUITING

Santa Monica, California, 90403, United States
Shanghai Sixth People's Hospital
COMPLETED

Shanghai, China
Stanford Medicine Cancer Institute
COMPLETED

Stanford, California, 94305, United States
Thomas Jefferson Hospital - Sidney Kimmel Cancer Center
COMPLETED

Philadelphia, Pennsylvania, 19107, United States
UW Medicine-Seattle Cancer Care Alliance
COMPLETED

Seattle, Washington, 98109, United States
University Campus Bio-Medico
COMPLETED

Rome, Italy
University of California Los Angeles
COMPLETED

Los Angeles, California, 90404, United States
University of Colorado Denver
COMPLETED

Aurora, Colorado, 80045, United States
University of Miami Sylvester Comprehensive Cancer Center
COMPLETED

Miami, Florida, 33136, United States
University of Michigan Comprehensive Cancer Center
COMPLETED

Ann Arbor, Michigan, 48109, United States
University of Palermo
COMPLETED

Palermo, Italy
University of Pittsburgh Medical Center
COMPLETED

Pittsburgh, Pennsylvania, 15219, United States
Vanderbilt University
COMPLETED

Nashville, Tennessee, 37203, United States
Washington University St. Louis
COMPLETED

St Louis, Missouri, 63130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.